A slimmed down patent reform bill clamping down on demand letters appears the final hope for legislation to get passed in this Congress. But some patent reform supporters are worried a small bill would make it even harder to pass comprehensive reform in the future while others say a pause in efforts to get reform passed is no bad thing
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
190 drugs face loss of exclusivity between 2026 and 2030, with the list including Bristol Myers Squibb’s blood-thinning drug Eliquis and immunotherapy medication Opdivo
Azhar Sadique and Kane Ridley, who founded the London office in 2023, are now both working in legal tech and AI-related roles, while another UK-based lawyer has also left
Vaping dispute, in which Stobbs and Brandsmiths are the representatives, tested how the UK's Human Rights Act can apply to injunctions restraining unjustified threats
Publication of the UPC’s annual report and adoption of the procedural rules of the Patent Mediation and Arbitration Centre were also among major developments